Patients with early BC still have a substantial risk of recurrence despite adjuvant ET, and the majority of patients with ABC undergoing first-line ET combined with CDK4/6 inhibitors experience disease progression within 5 years (3,4). The gene discussed is CDK4; the disease is aneurysmal bone cyst.